Trial of Adjunctive Vitamin D in Tuberculosis Treatment

Inclusion Criteria: * Suspected smear positive pulmonary tuberculosis. * Age 18 years or older. * Written informed consent to participate. Exclusion Criteria: * Known intolerance of vitamin D or first-line anti-tuberculous therapy. * Taking antituberculous therapy for more than six days in the six months preceding enrolment. * Taking the following medication in the month preceding enrolment: oral corticosteroid therapy, immunosuppressant therapy or cytotoxic therapy. * Taking the following medication at enrolment: benzothiadiazine derivatives, cardiac glycosides or antituberculous therapy other than rifampicin, isoniazid, pyrazinamide and ethambutol. * Diagnosis of any of the following: sarcoidosis, hyperparathyroidism, nephrolithiasis, pulmonary silicosis, HIV infection, liver failure, renal failure or malignancy * Infection with rifampicin-resistant organism (as demonstrated by rapid molecular testing) * Biochemical disturbance at enrolment: serum corrected calcium \>2.66 mmol/l, serum AST \>120 IU/l, total serum bilirubin \> 40 micromol/l or serum creatinine \> 250 micromol/l * Breastfeeding or pregnancy